PRNewsWire
12 Jun 2026, 01:57 UTC · 14w ago
Verdict
Headline leans bullish. We score 9926.HK +1.00 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
China's NMPA has approved Akeso's gumokimab (AK111) for the treatment of adult patients with moderate-to-severe plaque psoriasis.
More positive than 93% of claims this week
The NMPA has accepted a supplemental New Drug Application (sNDA) for gumokimab to treat active ankylosing spondylitis.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 64% of claims this week
Akeso is advancing manfidokimab in late-stage development and progressing its first-in-class IL-4R/ST2 bispecific antibody AK139.
So whatA strong late-stage pipeline reduces binary risk and supports long-term valuation beyond the current approval.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company received NMPA approval for gumokimab to treat plaque psoriasis, expanding its autoimmune disease portfolio.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
39m ago
—
No price for 9926.HK right now — the quote feed didn't answer.
9926.HK chart →
